
Peter Martin, MD, discusses selecting treatment for patients with high-risk mantle cell lymphoma.
Peter Martin, MD, discusses selecting treatment for patients with high-risk mantle cell lymphoma.
Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the landscape of mantle cell lymphoma (MCL).
Published: September 1st 2017 | Updated: